Related Experiment Video
Updated: Mar 22, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.3K
Summary
The combination of ado-trastuzumab emtansine (T-DM1) and pertuzumab shows promise for HER2-positive breast cancer. This neoadjuvant therapy outperformed standard treatment in the I-SPY 2 trial, suggesting future success in phase III studies.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- HER2-positive breast cancer is a subtype often associated with aggressive disease.
- Neoadjuvant therapy aims to shrink tumors before surgery, improving outcomes.
- Standard neoadjuvant therapies for HER2-positive breast cancer have limitations.
Discussion:
- The I-SPY 2 trial investigated the efficacy of ado-trastuzumab emtansine (T-DM1) plus pertuzumab as neoadjuvant treatment.
- This combination therapy demonstrated superior performance compared to standard neoadjuvant regimens.
- The findings were presented at the American Association for Cancer Research Annual Meeting 2016.
Key Insights:
- The T-DM1 plus pertuzumab combination significantly improved outcomes in HER2-positive breast cancer patients.
- This regimen offers a potential alternative to standard therapies, with potential for reduced toxicity.
- Early results suggest a high likelihood of success in subsequent phase III clinical trials.
Outlook:
- Further investigation in phase III trials is warranted to confirm these promising results.
- This combination therapy could represent a new standard of care for neoadjuvant treatment in HER2-positive breast cancer.
- The development of less toxic, more effective treatments is crucial for patients at risk of metastatic disease.
